Profile data is unavailable for this security.
About the company
Mangoceuticals, Inc. is focused on developing men’s and women’s health and wellness products and services via a secure telemedicine platform. The Company connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. It has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.
- Revenue in USD (TTM)466.92k
- Net income in USD-20.12m
- Incorporated2021
- Employees--
- LocationMangoceuticals Inc15110 Dallas Pkwy, Suite 600DALLAS 75248United StatesUSA
- Websitehttps://www.mangorx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ethema Health Corp | 15.42m | -1.44m | 2.32m | 70.00 | -- | -- | -- | 0.1503 | -0.0002 | -0.0002 | 0.002 | -0.0011 | 0.7242 | -- | 10.95 | 220,280.00 | -6.76 | 1.79 | -14.20 | -- | -- | -- | -9.34 | 3.51 | -- | 0.003 | 2.68 | -- | 12.58 | 75.64 | -282.77 | -- | -8.75 | -- |
| Aesthetic Medical Intl Hldg Grp Ltd(ADR) | 107.54m | -1.16m | 2.92m | 1.31k | -- | -- | 0.3972 | 0.0272 | -0.0213 | -0.0213 | 2.18 | -- | 1.47 | 28.52 | 74.39 | 82,155.05 | -2.45 | -30.31 | -10.38 | -77.31 | 44.14 | 50.05 | -1.67 | -28.93 | 0.2054 | 4.30 | 0.9902 | -- | 10.71 | -2.76 | 46.72 | -- | -16.53 | -- |
| Advanced Biomed Inc | 0.00 | -3.38m | 5.59m | 31.00 | -- | 1.73 | -- | -- | -0.1598 | -0.1598 | 0.00 | 0.1388 | 0.00 | -- | -- | 0.00 | -63.08 | -- | -154.97 | -- | -- | -- | -- | -- | -- | -9.33 | 0.00 | -- | -- | -- | -17.13 | -- | -- | -- |
| CompuMed Inc | 1.78m | -151.00k | 5.61m | 8.00 | -- | 44.12 | -- | 3.15 | -0.1337 | -0.1337 | 1.58 | 0.0997 | 2.38 | 36.71 | 4.83 | -- | -19.92 | -46.77 | -48.38 | -76.78 | 50.42 | 57.04 | -8.38 | -25.84 | 0.9493 | -2.93 | 0.7744 | -- | -1.73 | -5.71 | 64.41 | -- | -18.75 | -- |
| Mangoceuticals Inc | 466.92k | -20.12m | 6.09m | -- | -- | 0.3495 | -- | 13.05 | -3.03 | -3.03 | 0.065 | 1.13 | 0.0298 | -- | -- | -- | -126.57 | -- | -136.09 | -- | 60.62 | -- | -4,245.42 | -- | -- | -- | 0.0063 | -- | -15.81 | -- | 5.50 | -- | -- | -- |
| Univec Inc | -100.00bn | -100.00bn | 6.56m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -0.0113 | -- | -- | -- | -- | -- | -50.96 | -- | -- | -- | 17.47 | -- | -198.31 | 0.0051 | -- | -- | -- | -74.07 | -64.83 | 36.83 | -- | -- | -- |
| Xcelerate Inc | 3.96m | -296.19k | 6.78m | 1.00 | -- | 4.85 | -- | 1.71 | -0.0014 | -0.0014 | 0.0189 | 0.0032 | 1.51 | 6.13 | 3.90 | -- | -11.33 | 4.24 | -49.19 | -- | 71.71 | 74.10 | -7.48 | 1.93 | 0.4797 | -0.8218 | 0.7237 | -- | 6.63 | 10.43 | 17.00 | -- | 174.06 | -- |
| Biocorrx Inc | 948.36k | -5.16m | 7.11m | 5.00 | -- | -- | -- | 7.49 | -0.3254 | -0.3254 | 0.0602 | -0.668 | 0.232 | -- | 1.49 | -- | -104.32 | -370.28 | -- | -- | 62.17 | 67.86 | -449.74 | -4,584.39 | 0.0869 | -5.40 | -- | -- | -91.40 | -49.79 | -35.55 | -- | -- | -- |
| Interpace Biosciences Inc | 41.82m | 4.64m | 8.19m | 111.00 | 66.52 | -- | 1.56 | 0.1959 | 0.0278 | -0.0035 | 1.53 | -0.0673 | 3.21 | 12.75 | 6.31 | 376,747.80 | 39.18 | -21.04 | 750.62 | -42.31 | 64.57 | 55.74 | 12.21 | -16.71 | 1.35 | 24.13 | 1.44 | -- | 17.21 | 14.14 | 186.31 | -- | 46.23 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 420.67k | 2.73% |
| Geode Capital Management LLCas of 30 Sep 2025 | 87.97k | 0.57% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 68.86k | 0.45% |
| UBS Securities LLCas of 31 Dec 2025 | 46.17k | 0.30% |
| Ackerman Capital Advisors LLCas of 30 Sep 2025 | 34.50k | 0.22% |
| XTX Markets LLCas of 30 Sep 2025 | 28.51k | 0.19% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 18.96k | 0.12% |
| Csenge Advisory Group LLCas of 31 Dec 2025 | 10.00k | 0.07% |
| Sunbelt Securities, Inc.as of 30 Sep 2025 | 7.00k | 0.05% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 2.89k | 0.02% |
